Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ADPT vs ATYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATYR Captures Overall Composite Edge (34.3 SELL vs 43.2 HOLD), While ADPT Leads 4–2 on Growth & Valuation Pillars

ATYR Overall Winner 6-Pillar Tally: ADPT 4 – 2 ATYR Matrix Metrics: ADPT 5 – 3 ATYR

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Adaptive Biotechnologies Corporation (ADPT) on higher Unified Composite conviction (34.3/100 SELL vs. 43.2/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale, Profitability & Quality), while ADPT wins 4–2 across the 6-pillar growth and valuation breakdown. ADPT trades at $28.46 (N/M Forward P/E, -16.2% operating margin) versus ATYR at $4.83 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ADPT currently prints a higher short-term Unified Composite Score (43.2/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -16.2% operating margin) and revenue trajectory (+0.0% vs. -10.7% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADPT vs ATYR
ADPT NASDAQ
Adaptive Biotechnologies Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$28.46
+2.12% 1D
Market Cap $4.7B
TTM Revenue $298M
Forward P/E N/M
Beta / 30D Vol 1.71β · 59% Vol
Unified Composite Score
43.2 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.6% over 20 days), RSI 55
RSI-14: 54.6 · SMA20: $27.46 · SMA50: $27.06
ATYR NASDAQ Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.83
-7.82% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.57β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.4% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $4.36 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (ADPT 4 – 2 ATYR)

Columns: Metric · ADPT · ATYR
1. Valuation Multiples ADPT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 16.9x N/M
2. Growth & Scale ATYR
Revenue Growth (YoY) -10.7% +0.0%
Earnings Growth (YoY) -70.1% +0.0%
TTM Revenue (USD) $298M N/A
Market Cap $4.7B $15.6M
3. Profitability & Quality ATYR
Gross Margin 46.2% N/A
Operating Margin -16.2% 0.0%
Net Profit Margin -23.7% 0.0%
Return on Equity (ROE) -36.4% -93.7%
4. Balance Sheet & Cash Flow ADPT
Cash Generation (TTM) -$8.8M N/A
Cash Flow Margin -3.0% N/A
Net Cash / Leverage $333M Net Debt (2.32x D/E) $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ADPT
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 78.0% (36th %ile) 154.5% (36th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ADPT
OpEx & R&D Intensity 62.4% of Rev ($186M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADPT (5) vs ATYR (3)
Institutional Metric ADPT ATYR Criterion Row Edge
Market Capitalization
Scale
$4.7B $15.6M Larger Scale ADPT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-10.7% +0.0% Higher Growth ATYR
Operating Margin (TTM)
Profitability
-16.2% 0.0% Higher Margin ATYR
Net Profit Margin
Profitability
-23.7% 0.0% Higher Margin ATYR
Return on Equity (ROE)
Capital Efficiency
-36.4% -93.7% Higher ROE ADPT
52-Week Range Position
Momentum
81% ($12–$32) 60% ($0–$8) Stronger Trend ADPT
Beta / 30D Volatility
Risk Regime
1.71β · 59% Vol -9.57β · 13806% Vol Lower Realized Risk ADPT
Unified Institutional Score
Composite Signal
43.2 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite ADPT
Trailing 12M Revenue (USD)
Operating Scale
$298M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.8M ($333M Net Debt (2.32x D/E)) N/A ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +2694.22 pp
ADPT: +18.83% · ATYR: +2713.05%
3M Horizon ATYR +794.88 pp
ADPT: +11.65% · ATYR: +806.53%
6M Horizon ATYR +780.4 pp
ADPT: +119.6% · ATYR: +900.0%
1Y Horizon ATYR +439.59 pp
ADPT: +101.84% · ATYR: +541.43%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ADPT Revenue ATYR Revenue ADPT Op. Margin ATYR Op. Margin Margin Leader
FY2018 $60M N/A -89.4% N/A ADPT
FY2019 $90M $0M -92.1% -5445.0% ADPT
FY2020 $100M $10M -155.3% -152.2% ATYR
FY2021 $150M N/A -135.4% N/A ADPT
FY2022 $190M $10M -108.0% -446.8% ADPT
FY2023 $170M $0M -133.3% -15557.8% ADPT
FY2024 $180M $0M -90.8% -28899.6% ADPT
FY2025 $280M $0M -20.6% -40856.3% ADPT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADPT BREAKOUT
70d in phase · OBV ACCUMULATION
Current IV 78.0%
IV Percentile 36th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ADPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADPT Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and -16.2% operating margin.
OpEx & R&D Reinvestment 62.4% of Rev ($186M)
90D Engineering Disclosures 0 Published
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ADPT vs ATYR Key Questions & Quantitative Answers

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Adaptive Biotechnologies Corporation (ADPT) on higher Unified Composite conviction (34.3/100 SELL vs. 43.2/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale, Profitability & Quality), while ADPT wins 4–2 across the 6-pillar growth and valuation breakdown. ADPT trades at $28.46 (N/M Forward P/E, -16.2% operating margin) versus ATYR at $4.83 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ADPT currently prints a higher short-term Unified Composite Score (43.2/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -16.2% operating margin) and revenue trajectory (+0.0% vs. -10.7% YoY).

ATYR leads the Growth & Scale pillar: ADPT posts -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ADPT cumulative revenue shifted +366.7% while ATYR shifted +0.0%. In operating R&D and SG&A reinvestment, ADPT deploys 62.4% of Rev ($186M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.

ADPT screens cheaper on headline valuation multiples. ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.9x EV/Revenue (-3.0% FCF margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADPT (-36.4% ROE) versus ATYR (-93.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ADPT carries 78.0% implied volatility (36th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.71β · 59% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.57β · 13806% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.